Syndax Pharmaceuticals Files 2024 10-K
Ticker: SNDX · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 10-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, agreements, financials
TL;DR
Syndax Pharma dropped its 2024 10-K. Check out Bayer & Incyte deals.
AI Summary
Syndax Pharmaceuticals Inc. filed its 2024 10-K on March 3, 2025, reporting on its fiscal year ending December 31, 2024. The filing details its business operations, financial condition, and risk factors. Key agreements mentioned include a Purchase and Sale Agreement and a License Agreement with Bayer Pharma AG, alongside a collaboration with Incyte Corporation. The company's fiscal year end is December 31.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Syndax Pharmaceuticals' financial health and strategic direction for the 2024 fiscal year, including details on key agreements and potential risks.
Risk Assessment
Risk Level: medium — The filing likely contains standard business risks for a pharmaceutical company, including regulatory hurdles, clinical trial outcomes, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-03 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Syndax Pharmaceuticals Inc (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-03 (date) — Filing date
- Bayer Pharma AG (company) — Party to a License Agreement
- Incyte Corporation (company) — Party to a Collaboration Agreement
FAQ
What are the key terms of the License Agreement with Bayer Pharma AG?
The filing mentions a License Agreement with Bayer Pharma AG dated 2007-03-31, but specific terms are not detailed in this excerpt.
What is the nature of the Incyte Collaboration Agreement and Share Purchase Agreement?
The filing references an 'IncyteCollaborationAgreementAndSharePurchaseAgreement' for the period 2022-01-01 to 2022-12-31, indicating a past collaboration and share purchase.
Did Syndax Pharmaceuticals enter into any new significant agreements in 2024?
The filing mentions a 'PurchaseAndSaleAgreement' for the period 2024-01-01 to 2024-12-31, suggesting a significant agreement was active during this time.
What was the company's financial performance regarding Net Product Revenues in 2024?
The filing indicates 'NetProductRevenues' were reported for the period 2024-01-01 to 2024-12-31.
Are there any disclosed subsequent events after the fiscal year end?
Yes, the filing notes 'SubsequentEventMember' related to the 'EmployeeStockPurchasePlanMember' effective from 2025-01-01.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding Syndax Pharmaceuticals Inc (SNDX).